ClinicalTrials.gg
Not yet recruitingNCT06002841Updated Aug 21, 2023

Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure

A Phase 1/2 interventional study of intravenous treatment with EVs and intravenous treatment with placebo solution in Severe Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS) and Pneumonia, sponsored by D'Or Institute for Research and Education. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by D'Or Institute for Research and Education · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil — 3 open to participants now, 4 under way, 2 of them phase 3. Severe Acute Respiratory Syndrome · Brazil.

Planned enrollment
22nd of 26
15 · median 279
Started
2024
the only one that year
Phase 1/2
2 of 29
1 open now
Registered
29th of 29
by date
Lead sponsor
1 of 29
D'Or Institute for Research and Education

Among the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil, this one is the 22nd largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 1/2, and was the 29th registered.

Severe Acute Respiratory Syndrome

376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.

Browse Severe Acute Respiratory Syndrome studies →

Open to participants now

3 of the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil, or all of them as a file.
02

Study summary

This is a phase I/II, randomized, double-blind, placebo-controlled clinical trial that will evaluate the safety and potential efficacy of therapy with extracellular vesicles (EVs) obtained from mesenchymal stromal cells (MSCs), patients with moderate to severe acute respiratory distress syndrome due to COVID-19 or other etiology. Participants will be allocated to receive EVs obtained from MSCs or placebo (equal volume of Plasma-Lyte A). Blinding will cover the participants, the multidisciplinary intensive care team and the investigators.

Read the detailed description

The studied population will consist of 15 patients diagnosed with acute respiratory failure syndrome admitted to the intensive care unit of Hospital São Rafael. This research aims to assess the safety and potential effectiveness of intravenous therapy using extracellular vesicles derived from mesenchymal cells in patients with moderate to severe acute respiratory distress syndrome. The treatment group will receive intravenous administration of extracellular vesicles obtained from mesenchymal cells, while the control group will receive a placebo.

EV group: will consist of 10 participants who will receive two infusions of 25 mL of the investigational product (Plasma-Lyte A solution containing EVs obtained from MSCs), intravenously, at intervals of 48 h.

Placebo group: will consist of 5 participants who will receive an equal volume of Plasma-Lyte A, intravenously, following the same schedule as the IV group: two infusions with an interval of 48 hours.

03

Conditions studied

  • Severe Acute Respiratory Syndrome (SARS)
  • Acute Respiratory Distress Syndrome (ARDS)
  • Pneumonia

Keywords

  • SARS-CoV-2
  • intravenous therapy
  • extracellular vesicles
  • ARDS
  • mesenchymal cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years old;
  • Chest CT radiological image with ground-glass opacities or chest X-ray with - bilateral infiltrates characteristic of pulmonary edema;
  • In invasive mechanical ventilation with PEEP 5 cm H2O and PaO2/FiO2\<250mmHg;
  • Respiratory failure not explained by cardiac causes or fluid overload.

Exclusion criteria

Exclusion Criteria:

  • Unable to provide ;
  • Pregnancy or breastfeeding;
  • Patients with active who have received chemotherapy in the last 2 years;
  • of less than 6 months or in exclusive palliative care;
  • Severe liver failure, with a score > 12;
  • Previous renal failure: patients already undergoing dialysis or patients with \< 30ml/min/1.73 m2
  • Clinical or radiological suspicion of tuberculosis;
  • Chronic respiratory failure;
  • Use of ECMO;
  • Moribund (high probability of death within the next 48 hours).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    EV group

    will consist of 10 participants who will receive two infusions of 25 mL of the investigational product (Plasma-Lyte A solution containing EVs obtained from MSCs), intravenously, at intervals of 48 h.

    Biological: intravenous treatment with EVs

  • Placebo comparator
    Placebo group

    will consist of 5 participants who will receive an equal volume of Plasma-Lyte A, intravenously, following the same schedule as the IV group: two infusions with an interval of 48 hours.

    Biological: intravenous treatment with placebo solution

Interventions

  • Biologicalintravenous treatment with EVs

    intravenous treatment with extracellular vesicles

  • Biologicalintravenous treatment with placebo solution

    intravenous treatment with placebo solution (without extracellular vesicles)

06

What researchers measure

Primary outcomes

  1. Measure administration of extracellular vesicles (EVs) up to 28 days

    Measure as reported adverse events up to 28 days after treatment or placebo administration to evaluate safety of treatment

    Time frame: 28 days

Secondary outcomes

  1. All-cause mortality

    at days 14 and 28 after randomization;

    Time frame: Day 14 and day 28

  2. Variation in the Ratio PaO2/FiO2

    PaO2 (arterial partial pressure of oxygen)/FiO2 (fraction of inspired oxygen) on the day of randomization and at 24 hours, 48 hours and 7 days after the first infusion;

    Time frame: Baseline, day 01, day 02 and day 07

  3. Variation in the SOFA index

    Variation in the SOFA index (Assessment of Sequential Organ Failure) at the time of randomization and during follow-up until discharge from the intensive care unit;

    Time frame: day 01, day 02, day 07, day 09, day 14 and day 29

  4. Exploratory laboratory analysis

    variation in total and differential laboratory analysis.

    Time frame: 30 days

  5. Duration of the period of hospitalization

    from hospital time in the intensive care unit (ICU)

    Time frame: 30 days

  6. Duration of the period of ICU ventilation

    If applicable,will be measured the time of mechanical ventilation.

    Time frame: 30 days

07

Study locations

1 site
08

References and documents

Publications

  • Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. Cell Mol Neurobiol. 2016 Apr;36(3):301-12. doi: 10.1007/s10571-016-0366-z. Epub 2016 Apr 6. PubMed 27053351 ↗
  • Alipoor SD, Mortaz E, Garssen J, Movassaghi M, Mirsaeidi M, Adcock IM. Exosomes and Exosomal miRNA in Respiratory Diseases. Mediators Inflamm. 2016;2016:5628404. doi: 10.1155/2016/5628404. Epub 2016 Sep 25. PubMed 27738390 ↗
  • Antunes MA, Braga CL, Oliveira TB, Kitoko JZ, Castro LL, Xisto DG, Coelho MS, Rocha N, Silva-Aguiar RP, Caruso-Neves C, Martins EG, Carvalho CF, Galina A, Weiss DJ, Lapa E Silva JR, Lopes-Pacheco M, Cruz FF, Rocco PRM. Mesenchymal Stromal Cells From Emphysematous Donors and Their Extracellular Vesicles Are Unable to Reverse Cardiorespiratory Dysfunction in Experimental Severe Emphysema. Front Cell Dev Biol. 2021 May 31;9:661385. doi: 10.3389/fcell.2021.661385. eCollection 2021. PubMed 34136481 ↗
  • de Castro LL, Xisto DG, Kitoko JZ, Cruz FF, Olsen PC, Redondo PAG, Ferreira TPT, Weiss DJ, Martins MA, Morales MM, Rocco PRM. Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma. Stem Cell Res Ther. 2017 Jun 24;8(1):151. doi: 10.1186/s13287-017-0600-8. PubMed 28646903 ↗
  • Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner DE, Coffey A, Antunes M, Robinson KL, Mitsialis SA, Kourembanas S, Thane K, Hoffman AM, McKenna DH, Rocco PR, Weiss DJ. Systemic Administration of Human Bone Marrow-Derived Mesenchymal Stromal Cell Extracellular Vesicles Ameliorates Aspergillus Hyphal Extract-Induced Allergic Airway Inflammation in Immunocompetent Mice. Stem Cells Transl Med. 2015 Nov;4(11):1302-16. doi: 10.5966/sctm.2014-0280. Epub 2015 Sep 16. PubMed 26378259 ↗
  • De Jong OG, Van Balkom BW, Schiffelers RM, Bouten CV, Verhaar MC. Extracellular vesicles: potential roles in regenerative medicine. Front Immunol. 2014 Dec 3;5:608. doi: 10.3389/fimmu.2014.00608. eCollection 2014. PubMed 25520717 ↗
  • Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, Epple M, Horn PA, Beelen DW, Giebel B. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014 Apr;28(4):970-3. doi: 10.1038/leu.2014.41. No abstract available. PubMed 24445866 ↗
  • Lanyu Z, Feilong H. Emerging role of extracellular vesicles in lung injury and inflammation. Biomed Pharmacother. 2019 May;113:108748. doi: 10.1016/j.biopha.2019.108748. Epub 2019 Mar 14. PubMed 30877881 ↗
  • Lasser C, Jang SC, Lotvall J. Subpopulations of extracellular vesicles and their therapeutic potential. Mol Aspects Med. 2018 Apr;60:1-14. doi: 10.1016/j.mam.2018.02.002. Epub 2018 Feb 16. PubMed 29432782 ↗
  • Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019 Sep;76(17):3323-3348. doi: 10.1007/s00018-019-03125-1. Epub 2019 May 4. PubMed 31055643 ↗
  • Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013 Feb 18;200(4):373-83. doi: 10.1083/jcb.201211138. PubMed 23420871 ↗
  • Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020 Jun 15;29(12):747-754. doi: 10.1089/scd.2020.0080. Epub 2020 May 12. PubMed 32380908 ↗
  • Silva JD, de Castro LL, Braga CL, Oliveira GP, Trivelin SA, Barbosa-Junior CM, Morales MM, Dos Santos CC, Weiss DJ, Lopes-Pacheco M, Cruz FF, Rocco PRM. Mesenchymal Stromal Cells Are More Effective Than Their Extracellular Vesicles at Reducing Lung Injury Regardless of Acute Respiratory Distress Syndrome Etiology. Stem Cells Int. 2019 Aug 21;2019:8262849. doi: 10.1155/2019/8262849. eCollection 2019. PubMed 31531026 ↗
  • Shi MM, Yang QY, Monsel A, Yan JY, Dai CX, Zhao JY, Shi GC, Zhou M, Zhu XM, Li SK, Li P, Wang J, Li M, Lei JG, Xu D, Zhu YG, Qu JM. Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. J Extracell Vesicles. 2021 Aug;10(10):e12134. doi: 10.1002/jev2.12134. Epub 2021 Aug 14. PubMed 34429860 ↗
  • D'Souza-Schorey C, Schorey JS. Regulation and mechanisms of extracellular vesicle biogenesis and secretion. Essays Biochem. 2018 May 15;62(2):125-133. doi: 10.1042/EBC20170078. Print 2018 May 15. PubMed 29666210 ↗
  • Tieu A, Lalu MM, Slobodian M, Gnyra C, Fergusson DA, Montroy J, Burger D, Stewart DJ, Allan DS. An Analysis of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Preclinical Use. ACS Nano. 2020 Aug 25;14(8):9728-9743. doi: 10.1021/acsnano.0c01363. Epub 2020 Aug 4. PubMed 32697573 ↗
  • Wiklander OP, Nordin JZ, O'Loughlin A, Gustafsson Y, Corso G, Mager I, Vader P, Lee Y, Sork H, Seow Y, Heldring N, Alvarez-Erviti L, Smith CI, Le Blanc K, Macchiarini P, Jungebluth P, Wood MJ, Andaloussi SE. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015 Apr 20;4:26316. doi: 10.3402/jev.v4.26316. eCollection 2015. PubMed 25899407 ↗
  • Zhou T, He C, Lai P, Yang Z, Liu Y, Xu H, Lin X, Ni B, Ju R, Yi W, Liang L, Pei D, Egwuagu CE, Liu X. miR-204-containing exosomes ameliorate GVHD-associated dry eye disease. Sci Adv. 2022 Jan 14;8(2):eabj9617. doi: 10.1126/sciadv.abj9617. Epub 2022 Jan 12. PubMed 35020440 ↗
  • Zhu YG, Feng XM, Abbott J, Fang XH, Hao Q, Monsel A, Qu JM, Matthay MA, Lee JW. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells. 2014 Jan;32(1):116-25. doi: 10.1002/stem.1504. PubMed 23939814 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2024; primary completion for Jun 2025, 16 months later.

Of 11 phase 1/2 interventional studies under Severe Acute Respiratory Syndrome, half reached primary completion within 5 months of starting (the median); a quarter within 3 and three quarters within 13. This study's planned 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2023
First posted
Aug 21, 2023
StartEst.
Feb 1, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06002841
Lead sponsor
D'Or Institute for Research and Education
Collaborators
Hospital Sao Rafael, Rio de Janeiro State Research Supporting Foundation (FAPERJ), Oswaldo Cruz Foundation
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Feb 1, 2024 (estimated)
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Aug 21, 2023

Study contacts

Carolina Nonaka, phD
Contact
carolina.nonaka@hsr.com.br
+55 (71) 3281-6970
Ingrid Barbosa, B.Sc
Contact
nape@idor.org
+551121098855
Bruno Souza, M.D
principal investigator · Instituto D'Or de Pesquisa e Ensino (IDOR), Salvador, Brazil
Patrícia Rocco, M.D
principal investigator · Universidade Federal do Rio de Janeiro (UFRJ)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion